217 related articles for article (PubMed ID: 19440163)
1. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
2. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
3. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
4. Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis.
Song JH; Choi CH; Yeom HJ; Hwang SY; Kim TS
Life Sci; 2006 Jun; 79(2):193-202. PubMed ID: 16458935
[TBL] [Abstract][Full Text] [Related]
5. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
7. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
8. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
9. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ
Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928
[TBL] [Abstract][Full Text] [Related]
10. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
[TBL] [Abstract][Full Text] [Related]
12. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
Ji Q; Chang L; VanDenBerg D; Stanczyk FZ; Stolz A
Prostate; 2003 Mar; 54(4):275-89. PubMed ID: 12539226
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
14. Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Amin SA; Huang CC; Reierstad S; Lin Z; Arbieva Z; Wiley E; Saborian H; Haynes B; Cotterill H; Dowsett M; Bulun SE
Mol Cell Endocrinol; 2006 Jul; 253(1-2):44-55. PubMed ID: 16735089
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes.
Hu Y; Pang E; Lai PB; Squire JA; MacGregor PF; Beheshti B; Albert M; Leung TW; Wong N
Int J Oncol; 2004 Nov; 25(5):1357-64. PubMed ID: 15492826
[TBL] [Abstract][Full Text] [Related]
17. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.
Heibein AD; Guo B; Sprowl JA; Maclean DA; Parissenti AM
BMC Cancer; 2012 Aug; 12():381. PubMed ID: 22938713
[TBL] [Abstract][Full Text] [Related]
18. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.
Marín YE; Seiberg M; Lin CB
Exp Dermatol; 2009 Jul; 18(7):611-8. PubMed ID: 19320734
[TBL] [Abstract][Full Text] [Related]
19. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
20. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
